Purpose: To evaluate the impact of the type of CDK4/6 inhibitor administered and comorbidities on the quality of life in patients with metastatic breast cancer, as well as the correlation between quality of life and patient outcomes. Materials and Methods: This prospective single-center study utilized four internationally validated questionnaires: the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Core Cancer Quality of Life Questionnaire), the Depression, Anxiety, and Stress Scale-21 (DASS-21), the Multidimensional Fatigue Inventory (MFI), and the Pittsburgh Sleep Quality Index (PSQI), administered to a cohort of 76 patients undergoing treatment for metastatic breast cancer with CDK4/6 inhibitors. Results: Ribociclib is associated with fewer insomnia problems and appears to provide better sleep quality compared to other CDK4/6 inhibitors. Mental fatigue and loss of appetite negatively influence patient survival. Patients with comorbidities reported more severe insomnia and constipation. Comorbidities are associated with a lower quality of life, reflected in greater fatigue, insomnia, and constipation, as well as increased scores for depression and stress. Conclusions: Assessing global quality of life in metastatic breast cancer patients is essential, as it can predict patient progression and should be integrated into every breast cancer unit.
目的：评估CDK4/6抑制剂类型及合并症对转移性乳腺癌患者生活质量的影响，以及生活质量与患者预后之间的相关性。材料与方法：本前瞻性单中心研究采用四种国际通用量表——欧洲癌症研究与治疗组织核心生活质量问卷（EORTC QLQ-C30）、抑郁-焦虑-压力量表21项版（DASS-21）、多维疲劳量表（MFI）及匹兹堡睡眠质量指数（PSQI），对76例接受CDK4/6抑制剂治疗的转移性乳腺癌患者队列进行评估。结果：与其他CDK4/6抑制剂相比，瑞博西利相关失眠问题较少，且可能提供更优的睡眠质量。精神疲劳与食欲减退对患者生存期产生负面影响。合并症患者报告更严重的失眠与便秘症状。合并症与较低生活质量相关，表现为更显著的疲劳、失眠、便秘症状，以及更高的抑郁与压力评分。结论：对转移性乳腺癌患者进行全面生活质量评估至关重要，因其可预测疾病进展，应纳入所有乳腺癌诊疗单元的标准实践。
肿瘤(癌症)患者之家